1/17/2023 7:02:51 AM
Alkermes Awarded Innovation Passport Designation By UK's MHRA For Nemvaleukin Alfa For Mucosal Melanoma Treatment
11/2/2022 7:03:50 AM
Alkermes Q3 GAAP Loss Per Share $0.39 And Non-GAAP EPS $0.02; Announces Intent To Separate Oncology Business
7/27/2022 7:26:11 AM
Alkermes plc (ALKS) Has Raised Its FY22 Revenue Estimate To $1,050 – $1,120 Mln From $1,000 – $1,090 Mln
7/27/2022 7:25:47 AM
Alkermes plc (ALKS) Has Raised Its FY22 EPS Estimate To 0.09 - 0.27 From -0.18 - 0.00
7/27/2022 7:04:58 AM
Alkermes Q2 GAAP Loss Per Share $0.18 And Non-GAAP EPS $0.06
7/6/2022 7:08:27 AM
Sarissa Capital Comments On Alkermes Annual Meeting; Supports New Alkermes Directors To Step Up
6/1/2022 7:01:40 AM
Alkermes Presents ARTISTRY-1 Data At 2022 ASCO Annual Meeting
5/27/2022 10:04:06 AM
Sarissa Capital Management Shocked By Alkermes' Sudden Announcement Of Its Slate Of Director Nominees
4/27/2022 7:03:37 AM
Alkermes Plc Q1 GAAP Loss Per Share $0.22; Non-GAAP EPS $0.12
2/17/2022 7:03:34 AM
Alkermes Presents New Data From Ongoing Phase 1/2 ARTISTRY-1 Trial For Nemvaleukin Alfa